Does the c-peptide level predict remission phase in type 1 diabetic children

Abstract EN

-Objective : To study the C-peptide level for prediction of remission phase and its role in management of newly diagnosed type 1 diabetic children.

Methods : A cohort study was conducted on 64 newly diagnosed type 1 diabetic children.

Children were classified into Group 1 (35 patients) who experienced remission and Group 2 (29 patients) who did not experience remission.

Fasting plasma C-peptide, fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were done for all patients.

Results : Prevalence of remission was 0.546 (35 / 64).

Fasting serum C-peptide of Group 1 at first, last visits and Group 2 were 163.25 ± 120.84, 358.25 ± 184.67 and 86.70 ± 63.51pmol / l respectively ; p<0.05.

Receiver Operating Characteristic (ROC) showed that the prevalence of remission phase was 0.594.

Plotting ROC curve for C-peptide among patients of both groups showed Area Under the Curve (AUC=0.82).

The ROC decision plot curve of best C-peptide true predictive values was 100-200 pmol / l.

Conclusions : Remission phase is prevalent in newly diagnosed type 1 diabetes pediatric patients.

The C-peptide level is sensitive and specific test to certain degree that we can trust its use to predict the remission phase in newly diagnosed patients.

The most considerable readings found to be 100-200 pmol / l, as prediction cut-off limit for diagnosis of honey moon period.

The C-peptide level may assist physician in adjusting the initial insulin dosage early after diagnosis of type 1 diabetes mellitus.